← Back to Search

Monoclonal Antibodies

Felzartamab for Lupus Nephritis

Phase 1
Recruiting
Research Sponsored by HI-Bio, A Biogen Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of Systemic Lupus Erythematosus (SLE) according to the 2019 European League Against Rheumatism (EULAR)/ American College of Rheumatology (ACR) criteria
Diagnosis of International Society of Nephrology/ Renal Pathology Society (ISN/RPS) 2003 Class III or IV LN as evidenced by renal biopsy performed within 1 year prior to or during screening, either with or without the presence of Class V LN
Must not have
A previous kidney transplant or other organ transplant, or planned transplant within study treatment period
Currently requiring hemodialysis or peritoneal dialysis or expected to require dialysis during the study treatment period
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial studies a drug to treat Lupus Nephritis in people who haven't responded to other treatments.

Who is the study for?
This trial is for people with Lupus Nephritis who have tried at least one standard treatment without success. They must have a specific type of kidney inflammation diagnosed by biopsy within the last year, protein in their urine, and kidneys that are still working moderately well. People can't join if they have very fast-worsening kidney disease, more than half of their kidney filters scarred, are on or will need dialysis soon, or had an organ transplant.
What is being tested?
The study is testing Felzartamab alongside usual treatments for Lupus Nephritis to see how safe it is and how well patients tolerate it. Participants will receive Felzartamab plus the standard care that's typically given for this condition.
What are the potential side effects?
While not specified here, similar drugs often cause side effects like reactions where the drug enters the body (infusion reactions), infections due to a weakened immune system, nausea, headaches and possibly allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with SLE according to the 2019 EULAR/ACR criteria.
Select...
My kidney biopsy shows I have a specific type of lupus nephritis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had or am planning to have an organ transplant.
Select...
I am on or will need dialysis during the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2020 Phase 1 & 2 trial • 91 Patients • NCT01421186
52%
Plasma cell myeloma
42%
Anaemia
35%
Fatigue
32%
Nausea
26%
Leukopenia
23%
Diarrhea
19%
Infusion related reaction
19%
Nasopharyngitis
19%
Headache
16%
Lymphopenia
16%
Musculoskeletal chest pain
16%
Pyrexia
16%
Hypokalaemia
13%
Neutropenia
13%
Constipation
13%
Plasma Cell Myeloma
13%
Dyspnoea
13%
Infusion-related reaction
13%
Bronchitis
13%
Vomiting
13%
Hypertension
10%
Hypophosphataemia
10%
Night sweats
10%
Cough
10%
Hyperhidrosis
10%
Bone pain
10%
Tachycardia
10%
Thrombocytopenia
10%
Blood lactate dehydrogenase increased
10%
Upper respiratory tract infection
10%
Oedema peripheral
10%
Muscle spasm
10%
Dizziness
10%
Hypotension
10%
Pain in extremity
6%
Dyspnoea exertional
6%
Rhinitis
6%
Nasal congestion
6%
Acute Kidney Injury
6%
Blood creatinine phosphokinase increased
6%
Blood creatinine increased
6%
Respiratory tract infection
6%
Hyperuricaemia
6%
Myalgia
6%
Paraesthesia
6%
Pruritus
6%
Haematoma
6%
Hyperphosphataemia
6%
Rhinorrhoea
6%
Infection
3%
Visual impairment
3%
Confusional state
3%
Vision blurred
3%
Upper Respiratory Tract Infection
3%
Polyneuropathy
3%
Disease progression
3%
Oral herpes
3%
Angina pectoris
3%
Cardiac Failure
3%
Epistaxis
3%
Renal Failure
3%
Renal failure
3%
Spinal Stenosis
3%
Urinary tract infection
3%
Dry mouth
3%
Decreased appetite
3%
Back pain
3%
Erythema
3%
Petechiae
3%
Insomnia
3%
Hyponatraemia
3%
Spinal stenosis
3%
Fall
3%
Pneumonia
3%
Amylase increased
3%
Oropharyngeal pain
3%
Vertigo
3%
Neutrophilia
3%
Leukocytosis
3%
Pain
3%
Dysaesthesia
3%
Abdominal pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Part A: MOR03087 Biweekly Dose Escalation
Part B: MOR03087 Weekly Dose Escalation
Part C: MOR03087 Plus Dexamethasone
Part D: MOR03087 Plus Pomalidomide + Dexamethasone
Part E: MOR03087 Plus Lenalidomide + Dexamethasone

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: FelzartamabExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Felzartamab
2021
Completed Phase 2
~80

Find a Location

Who is running the clinical trial?

HI-Bio, A Biogen CompanyLead Sponsor
6 Previous Clinical Trials
281 Total Patients Enrolled
HI-BioLead Sponsor
5 Previous Clinical Trials
161 Total Patients Enrolled
HI-Bio Clinical Program LeadStudy DirectorHI-Bio, A Biogen Company
4 Previous Clinical Trials
139 Total Patients Enrolled
~12 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top